Leerink Partnrs Expects Stronger Earnings for Inari Medical

Inari Medical, Inc. (NASDAQ:NARI - Free Report) - Research analysts at Leerink Partnrs upped their Q4 2024 EPS estimates for shares of Inari Medical in a research note issued to investors on Monday, October 28th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.02 per share for the quarter, up from their previous estimate of ($0.07). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Inari Medical's current full-year earnings is ($0.75) per share. Leerink Partnrs also issued estimates for Inari Medical's Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS and FY2025 earnings at $0.19 EPS.

A number of other analysts also recently issued reports on NARI. Stifel Nicolaus started coverage on shares of Inari Medical in a report on Tuesday, September 17th. They set a "hold" rating and a $50.00 price objective for the company. Piper Sandler boosted their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a research note on Tuesday. William Blair started coverage on shares of Inari Medical in a research report on Thursday, July 25th. They set an "outperform" rating for the company. Robert W. Baird lifted their target price on shares of Inari Medical from $66.00 to $67.00 and gave the company an "outperform" rating in a research report on Tuesday. Finally, Wells Fargo & Company lowered their price objective on shares of Inari Medical from $84.00 to $65.00 and set an "overweight" rating for the company in a report on Wednesday, July 31st. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Inari Medical presently has an average rating of "Hold" and a consensus price target of $58.89.

Inari Medical Trading Up 2.8 %

Shares of NARI traded up $1.30 during trading hours on Thursday, reaching $48.40. 1,098,908 shares of the stock traded hands, compared to its average volume of 1,004,413. The stock has a fifty day simple moving average of $43.50 and a 200 day simple moving average of $45.97. Inari Medical has a 52 week low of $36.73 and a 52 week high of $67.13. The company has a market cap of $2.82 billion, a price-to-earnings ratio of -36.48 and a beta of 1.00.

Inari Medical (NASDAQ:NARI - Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The business had revenue of $145.82 million during the quarter, compared to the consensus estimate of $143.96 million.

Institutional Trading of Inari Medical

Several large investors have recently made changes to their positions in NARI. State of Alaska Department of Revenue lifted its stake in Inari Medical by 462.4% during the 1st quarter. State of Alaska Department of Revenue now owns 31,095 shares of the company's stock worth $1,491,000 after acquiring an additional 25,566 shares in the last quarter. Maryland State Retirement & Pension System acquired a new position in Inari Medical during the first quarter worth approximately $886,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Inari Medical during the first quarter worth approximately $30,000. Texas Permanent School Fund Corp increased its holdings in shares of Inari Medical by 1.5% in the first quarter. Texas Permanent School Fund Corp now owns 44,858 shares of the company's stock valued at $2,152,000 after purchasing an additional 664 shares during the period. Finally, Swiss National Bank increased its holdings in shares of Inari Medical by 0.6% in the first quarter. Swiss National Bank now owns 102,300 shares of the company's stock valued at $4,908,000 after purchasing an additional 600 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares in the company, valued at approximately $22,265,500. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Andrew Hykes sold 3,000 shares of the business's stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the sale, the chief executive officer now owns 445,310 shares in the company, valued at approximately $22,265,500. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.05, for a total value of $2,002,000.00. Following the sale, the director now directly owns 561,233 shares of the company's stock, valued at $28,089,711.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 131,000 shares of company stock worth $6,161,340 over the last three months. 10.60% of the stock is owned by insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.